142 related articles for article (PubMed ID: 36797154)
21. [Efficacy and safety of daratumumab in patients with relapsed/refractory multiple myeloma].
Zhao AL; Tang WJ; Li Y; Liao Y; Li H; Wang J; Shen K; Yang YF; Xu J; Zhang L; Zheng YH; Niu T
Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(41):3304-3311. PubMed ID: 36319183
[No Abstract] [Full Text] [Related]
22. A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly.
Leleu X; Chari A; Richard S; Khurana M; Yusuf A; Usmani SZ
Expert Rev Hematol; 2021 Dec; 14(12):1049-1058. PubMed ID: 34546844
[TBL] [Abstract][Full Text] [Related]
23. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Kampfenkel T; Liu W; Wang J; Kosh M; Tran N; Carson R; Sonneveld P
Lancet Haematol; 2023 Oct; 10(10):e813-e824. PubMed ID: 37793772
[TBL] [Abstract][Full Text] [Related]
25. DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma.
Goldsmith SR; Fiala MA; Wang B; Schroeder MA; Wildes TM; Ghobadi A; Stockerl-Goldstein K; Vij R
Ann Hematol; 2020 May; 99(5):1041-1048. PubMed ID: 32130471
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma.
Van Oekelen O; Parekh S; Cho HJ; Vishnuvardhan N; Madduri D; Richter J; Ip C; Lau K; Florendo E; Mancia IS; Thomas J; Verina D; Chan E; Zarychta K; La L; Strumolo G; Melnekoff DT; Leshchenko VV; Kim-Schulze S; Couto S; Wang M; Pierceall WE; Thakurta A; Laganà A; Jagannath S; Chari A
Leuk Lymphoma; 2020 Sep; 61(9):2208-2215. PubMed ID: 32812822
[TBL] [Abstract][Full Text] [Related]
27. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Landgren O; Hultcrantz M; Diamond B; Lesokhin AM; Mailankody S; Hassoun H; Tan C; Shah UA; Lu SX; Salcedo M; Werner K; Rispoli J; Caple J; Sams A; Verducci D; Jones K; Concepcion I; Ciardello A; Chansakul A; Schlossman J; Tavitian E; Shekarkhand T; Harrison A; Piacentini C; Rustad EH; Yellapantula V; Maclaughlan K; Maura F; Landau HJ; Scordo M; Chung DJ; Shah G; Lahoud OB; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Derkach A; Giralt SA; Korde N
JAMA Oncol; 2021 Jun; 7(6):862-868. PubMed ID: 33856405
[TBL] [Abstract][Full Text] [Related]
28. Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.
Zhou X; Steinhardt MJ; Grathwohl D; Meckel K; Nickel K; Leicht HB; Krummenast F; Einsele H; Rasche L; Kortüm KM
Cancer Med; 2020 Aug; 9(16):5819-5826. PubMed ID: 32608149
[TBL] [Abstract][Full Text] [Related]
29. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma.
Richard S; Jagannath S; Cho HJ; Parekh S; Madduri D; Richter J; Chari A
Expert Rev Hematol; 2021 Jan; 14(1):31-45. PubMed ID: 33331794
[No Abstract] [Full Text] [Related]
30. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
[TBL] [Abstract][Full Text] [Related]
31. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos MV; Mark TM; Qi M; Schecter J; Amin H; Qin X; Deraedt W; Ahmadi T; Spencer A; Sonneveld P;
N Engl J Med; 2016 Aug; 375(8):754-66. PubMed ID: 27557302
[TBL] [Abstract][Full Text] [Related]
32. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.
Trudel S; Tessoulin B; Jullien M; Blin N; Gastinne T; Mahé B; Dubruille V; Bonnet A; Lok A; Chevallier P; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Le Gouill S; Moreau P; Touzeau C
Ann Hematol; 2019 Jun; 98(6):1441-1447. PubMed ID: 30874851
[TBL] [Abstract][Full Text] [Related]
33. Outcomes with panobinostat in heavily pretreated multiple myeloma patients.
Pan D; Mouhieddine TH; Upadhyay R; Casasanta N; Lee A; Zubizarreta N; Moshier E; Richter J
Semin Oncol; 2023; 50(1-2):40-48. PubMed ID: 37005144
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma.
Abdallah AO; Mohyuddin GR; Mahmoudjafari Z; Atrash S; Kawsar H; Sigle M; Shune L; McGuirk J; Ganguly S
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e212-e219. PubMed ID: 33051166
[TBL] [Abstract][Full Text] [Related]
35. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.
Dimopoulos MA; Oriol A; Nahi H; San-Miguel J; Bahlis NJ; Usmani SZ; Rabin N; Orlowski RZ; Suzuki K; Plesner T; Yoon SS; Ben Yehuda D; Richardson PG; Goldschmidt H; Reece D; Ahmadi T; Qin X; Garvin Mayo W; Gai X; Carey J; Carson R; Moreau P
J Clin Oncol; 2023 Mar; 41(8):1590-1599. PubMed ID: 36599114
[TBL] [Abstract][Full Text] [Related]
36. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Mark TM; Forsberg PA; Rossi AC; Pearse RN; Pekle KA; Perry A; Boyer A; Tegnestam L; Jayabalan D; Coleman M; Niesvizky R
Blood Adv; 2019 Feb; 3(4):603-611. PubMed ID: 30792190
[TBL] [Abstract][Full Text] [Related]
37. KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma.
Alsouqi A; Khan M; Dhakal B; Du L; Harrell S; Hari P; Cornell RF
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):526-535. PubMed ID: 33985931
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease.
Byun JM; Min CK; Kim K; Bang SM; Lee JJ; Kim JS; Yoon SS; Koh Y
J Hematol Oncol; 2022 Oct; 15(1):150. PubMed ID: 36274163
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma.
Iida S; Ichinohe T; Shinagawa A; Suzuki K; Takezako N; Aoki M
Int J Hematol; 2018 Apr; 107(4):460-467. PubMed ID: 29260507
[TBL] [Abstract][Full Text] [Related]
40. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Chari A; Suvannasankha A; Fay JW; Arnulf B; Kaufman JL; Ifthikharuddin JJ; Weiss BM; Krishnan A; Lentzsch S; Comenzo R; Wang J; Nottage K; Chiu C; Khokhar NZ; Ahmadi T; Lonial S
Blood; 2017 Aug; 130(8):974-981. PubMed ID: 28637662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]